FDA
No application listedNo application naming nadide or NAD as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications.
Drugs@FDA via openFDANAD+: chemistry, literature and regulatory status
Research-use information. This page summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.
What is NAD+?
NAD+ is nicotinamide adenine dinucleotide, a coenzyme found in all living cells. It carries electrons in reduction-oxidation reactions and is a cosubstrate for sirtuins, CD38 and poly(ADP-ribose) polymerases. It is not a peptide, and it is listed in the catalog as a research material for laboratory use only.
What are the chemical facts for NAD+?
- Name
- NAD+
- Also written
- β-NAD
- Structure
- Nicotinamide adenine dinucleotide (non-peptide)
- Molecular formula
C21H27N7O14P2- Average molecular weight
- 663.4 g/mol
- CAS number
53-84-9(confirmed in PubChem)- PubChem
- CID 5892
Chemistry checked against PubChem on 2026-10-05. Where the formula can be computed from the listed sequence, it was, and the two routes agree.
How does the literature describe the mechanism of NAD+?
- NAD+ is a coenzyme for redox reactions and an essential cofactor for non-redox NAD+-dependent enzymes including sirtuins, CD38 and poly(ADP-ribose) polymerases.[1],[3]
- Reviews describe NAD+ homeostasis, its biosynthesis pathways and the link between energy metabolism, mitochondria and the nucleus.[2],[4]
Receptor and pathway background: NAD+ metabolism and NNMT.
What has published research on NAD+ looked at?
4 studies are cited for NAD+. Each is labelled by design below, and each entry says what the paper measured.
- 4 review
PubMed returns 1232 records for the search terms published on the method page (270 of them with a review publication type, 7 with a clinical-trial publication type), checked 5 October 2026.
Studies are listed by what they measured. Papers whose titles state an amount or schedule, or describe a clinical outcome of an approved medicine, are not listed. This is a wording rule, not a quality filter; see the method page.
What is the regulatory status of NAD+?
EMA
No centrally authorised medicine listedNo centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names nadide or nicotinamide adenine dinucleotide as an active substance. National authorisations are not in this dataset.
EMA medicines dataMHRA
No product document foundNo SmPC, PIL or PAR document in MHRA Products matches the exact name "nadide". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents.
MHRA ProductsWADA
Not namedThe WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport.
WADA Prohibited List 2026A regulator record is information about a database entry. It is not advice and not a statement that any use is lawful or unlawful in any country. How regulators approach research peptides.
Data dates: regulatory records 2026-10-05; WADA list 2026-10-05.
Which studies are cited for NAD+?
[1] Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22:119-141.
Review of NAD+ metabolism and the roles of NAD+-dependent enzymes (sirtuins, CD38, PARPs) in cellular processes during ageing.
[2] Katsyuba E, Romani M, Hofer D, Auwerx J. NAD+ homeostasis in health and disease. Nat Metab. 2020;2:9-31.
Review of NAD+ homeostasis, biosynthesis pathways and sirtuin signalling.
[3] Verdin E. NAD⁺ in aging, metabolism, and neurodegeneration. Science. 2015;350:1208-13.
Review of NAD+ as a coenzyme and as a cosubstrate for sirtuins and PARPs.
[4] Cantó C, Menzies KJ, Auwerx J. NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. Cell Metab. 2015;22:31-53.
Review of NAD+ metabolism linking energy homeostasis, mitochondria and the nucleus.
Data dates: citations read from PubMed 2026-10-05.
Where else in the research library is NAD+ covered?
Who wrote this page and how is it checked?
Peptency editorial team, last reviewed 5 October 2026. Citations are read back from PubMed, chemistry is checked against PubChem, and regulator records are read from each regulator's own database on the dates shown. The method page lists every source, search term and rule. Corrections are welcome through the contact details on the About page.